Clinical Study of HEC68498 in Patients With Advanced Refractory Solid Tumors

Summary

Clinical study of HEC68498 in patients with advanced refractory solid tumors. The primary objective is to determine the maximum tolerated dose and dose limiting toxicity of HEC68498 in patients with advanced refractory solid tumors

Timeline

Start

2019-02-27

Primary completion

2021-02-26

Completion

2021-03-26

Drugs

Indications